Rishi Gupta

Prior to his tenure at OrbiMed, Rishi was a healthcare investment banker at Raymond James & Associates, served as manager of corporate development at Veritas Medicine, and was a summer associate at Wachtell, Lipton, Rosen & Katz.

Rishi has published scientific articles on the mechanisms of HIV entry into host cells and legal articles on intellectual property laws in the developing world.

In addition to Enliven, he serves or has served on the boards of Pionyr Immunotherapeutics, Verona Pharma, Turnstone Biologics, NeuroPace, Avitide, Modis Therapeutics, Dimension Therapeutics, Symbiomix Therapeutics, Attenua, ChemoCentryx, and Sientra.

Rishi has also been actively involved with OrbiMed’s investments in Acceleron Pharma, CoGenesys, Supernus Pharmaceuticals, Adimab, Receptos, Aragon Pharmaceuticals, Seragon Pharmaceuticals, Alector, Arsanis, Biotie, Invitae, and ORIC Pharmaceuticals.

Rishi earned a JD from the Yale Law School and an AB degree magna cum laude in Biochemical Sciences from Harvard College